News for 'ATNG' - (ATNG Completes Strategic Alliance)
FENTON, Mich., Oct 21, 2003 (BUSINESS WIRE) -- ATNG Inc. (OTCBB:ATNG.OB)
announced today that it has signed documents to acquire BlueKiwi Inc. and its
product line.
According to Mr. James Barger, CEO of BlueKiwi, "The nutraceutical product line
is based on 12 years of research with chronic fatigue clients led by Dr. L.E.
Lindner and scientists at Pathobiotek Inc. The BlueKiwi trademark will be on
this line of nutraceuticals. We plan to launch the first three products,
"Inhibitor", and "Moderator" and "Enhancer" (packaged together), starting in
November 2003 through TV, Radio and Print advertising with a nationwide ad
campaign."
According to Dr. Simpson, CEO of ATNG Inc., "This strategic alliance is the last
step prior to the acquisition of Blue Kiwi. We have high expectations for
revenues and profits to be provided by Blue Kiwi. We plan to complete the
acquisition when Blue Kiwi is profitable."
ABOUT ATNG
ATNG is considering additional strategic alliances with companies that will
complement its business strategies. Our new web site will soon provide a
communication link to those interested in our progress. We are acquiring media
for advertising our products. Web site: www.atnginfo.com. Contact information:
patho@chartermi.net.
Certain statements in this news release may contain forward-looking information
within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6
under the Securities Exchange Act of 1934 and are subject to the safe harbor
created by those rules. All statements, other than statements of fact, included
in this release, including, without limitation, statements regarding potential
future plans and objectives of the company, are forward-looking statements that
involve risks and uncertainties. There can be no assurance that such statements
will prove to be accurate and actual results and future events could differ
materially from those anticipated in such statements.
SOURCE: ATNG Inc.
CONTACT: ATNG, Inc.
Robert Simpson, 810-714-2978
patho@chartermi.net |
